Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

eResearchTechnology

eResearchTechnology, Inc. (eRT) is a provider of technology-based products and services that enable the pharmaceutical, biotechnological, medical device, and contract resource companies to collect, interpret, and distribute cardiac safety and clinical data more efficiently. The Company is a market leader in providing centralized electrocardiographic (diagnostic) services and a leading provider of technology and services designed to streamline the clinical trial process by enabling its customers to automate many parts of a clinical trial.


Contact Details:
1125 Route 22 West
Bridgewater
New Jersey
08807
United States of America
Tel:908-704-8010
Fax:908-704-8215
Email:eresearch@ert.com
WWW:

www.eresearchtechnology.com/




Loading...

Recent Publications by eResearchTechnology:

Sudden cardiac death in nephrology: focus on acquired long QT syndrome.
A compelling assessment of both short- and long-term cardiac safety is...
4th July, 2007
FACC, eResearchTechnology, Global Medical Affairs and UMDNJ-RWJMS, Nephrol Dial Transplant. 2007 Jan;22(1):12-4. Epub 2006 Nov 8.
DOI Direct Link
Cardiac repolarization and the safety of new drugs defined by electrocardiography.
A compelling assessment of both short- and long-term cardiac safety is...
18th January, 2007
eResearchTechnology Inc, 30 South 17th Street, Philadelphia, Pennsylvania, Clin Pharmacol Ther. 2007 Jan;81(1):108-13.
DOI Direct Link
Evaluation of vardenafil and sildenafil on cardiac repolarization.
This novel study evaluated the effects of vardenafil and sildenafil on QT...
26th June, 2004
University of Pennsylvania School of Medicine and eResearchTechnology Am J Cardiol. 2004 Jun 1;93(11):1378-83, A6.
DOI Direct Link
Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
OBJECTIVES: Certain GI prokinetic agents have been shown to affect cardiac...
19th October, 2002
University of Pennsylvania School of Medicine and eResearchTechnology, Am J Gastroenterol. 2002 Sep;97(9):2321-7.
DOI Direct Link

Press Releases on eResearchTechnology:

BioPortfolio Logo
ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 25th November, 2009 ERT
PHILADELPHIA, Nov. 25 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive
MedClean Technologies Announces Positive Cash Flow From Operations for Third Quarter 10th November, 2009 MedClean Technologies, Inc.
BETHEL, Conn., Nov. 10 /PRNewswire-FirstCall/ -- MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) today announced financial results for the Company's third quarter, the period ended
ERT Reports Third Quarter 2009 Results 29th October, 2009 eResearchTechnology, Inc.
-- ERT purchased 196,016 shares of its common stock at an average price of $5.49 under its approved stock repurchase program in the third quarter of 2009 at a total cost of $1.1
ERT to Announce 2009 Third Quarter Results on October 29, 2009 21st October, 2009 ERT
PHILADELPHIA, Oct. 21 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized ECG, ePRO, eClinical technology, and other services to the biopharmaceutical, medical device, and
ERT Launches New Online Gateway to Improve Cardiac Safety in Clinical Trials 7th July, 2009 ERT
PHILADELPHIA, July 7 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized ECG, ePRO, eClinical technology and other services to the biopharmaceutical, medical device and

BioNews Results for eResearchTechnology:

eResearchTechnology, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released
PR inside:  Nov 16 2009 9:58AM Matching: eresearchtechnolog
ERT Reports Third Quarter 2009 Results
KOTA Territory News:  Oct 30 2009 2:33AM Matching: eresearchtechnolog
Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Ana
Journal of Clinical Pharmacology:  Oct 21 2009 8:54PM Matching: eresearchtechnolog

eResearchTechnology (ERES) Financial information Links from Barchart

ERES Quote from from Barchart.com
ERES Chart from from Barchart.com
ERES Profile from from Barchart.com
ERES Opinion from from Barchart.com

View more eResearchTechnology finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 301 times since April 2007, the link to the organisation's website has been followed 56 times

Recent Search Terms used to find this page: 908-704-8215 | 908-704-8215 | .

Search for more companies in Bridgewater

Search for more companies in New Jersey



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for eResearchTechnology

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.